Archemix Corporation Initiates Phase 2a for Lead Aptamer Product Candidate ARC1779

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Archemix Corp., a privately-held biotechnology company working to develop aptamer-based therapeutics, announced today that it has initiated a Phase 2a clinical trial of its novel anti-von Willebrand Factor (VWF) aptamer, ARC1779. The trial is designed to evaluate the safety and efficacy of ARC1779 as a potential first-in-class anti-platelet agent in patients with carotid artery disease undergoing a surgical procedure known as carotid endarterectomy, or CEA.